Lab, cryo and inventory software runs the parts of an IVF clinic that handle biological material: the embryology bench, cryo storage and chain of custody, donor and ART bank records, and pharmacy stock. Each step is tracked so samples, medicines and donor data stay traceable. This hub covers embryology, cryo storage, donor and ART banks, and pharmacy stock.
The lab is where a fertility clinic's software gets tested. Everywhere else you're recording what happened to a person. Here you're recording what happened to a sample, which has no memory, cannot correct you and may sit in a tank for a decade before anyone checks whether the label was right.
Four things that get bundled together and shouldn't be confused.
Embryology workflow is the bench record: what was retrieved, what was mature, what fertilised, what developed and what got graded. Cryo is storage and traceability, where a sample lives and whether you can still find it. Donor and ART bank work adds screening, matching and consent chains that outlive the treatment cycle. Pharmacy and stock control is the supply side, which sounds like the boring one until a drug runs out mid-stimulation.
They're grouped because they share one property. Every one of them tracks a physical object through time, and the record is the only thing standing between the object and being lost.
Indian clinics operate under a hard limit that changes how storage has to be recorded. Gametes and embryos may be cryopreserved for up to ten years, after which they are allowed to perish or be donated, and extension beyond that requires permission from the National Board.
That makes expiry a scheduled event, not an exception. Every straw in your tank has a date attached to a legal consequence, and the software either surfaces it in advance or it doesn't.
Consent underneath it is more specific than most clinics realise. Written consent is required from all parties, and it has to cover disposition, meaning what happens to the material in the event of death or incapacity. That's not a signature at intake. It's a decision recorded per specimen, and it has to still be findable years later, attached to the right sample, when the people who signed it may no longer be reachable.
Donor rules add another linkage the record has to hold. A donor may donate to only one couple, and oocyte donation is limited to once in a lifetime. Enforcing that isn't a lab task, it's a data task, and it fails quietly if donor identity isn't unique across your system.
The ten year retention obligation for ART records covers more than notes. Images and slides fall inside it.
That's a storage question most clinics don't cost properly. Embryo images, time-lapse output where it's used, ultrasound captures and stained slides are large files with a ten year obligation attached. Ask where they live, whether they're in the record or on a lab machine, and what happens to them at migration. A record system that keeps the note and loses the image has kept part of a legal record.
Outside India the direction has been the same for years. The European Single European Code assigns coded identifiers to tissue and cell material so a sample can be traced across borders and across facilities. In the United States, establishments handling reproductive tissue register under 21 CFR Part 1271, with a partner donation exemption that narrows the scope but not the traceability logic.
None of that binds an Indian clinic directly. It matters anyway, because it's where donor material, cross-border patients and international accreditation eventually push everyone, and because it tells you what a mature traceability model looks like when someone has thought it through properly.
Electronic witnessing is the most oversold thing in the lab.
The systems work. What they don't do is remove manual labelling. Published evaluation of a decade of electronic witnessing use reports a mismatch rate around 0.251 percent per witnessing point and concludes that manual labelling of dishes and tubes remains necessary as a fallback when the system malfunctions or is used incorrectly. Actual mix-ups are extremely rare, in the range of 0.001 to 0.002 percent, which is precisely why the residual risk sits in process rather than in headline failure.
Two things follow that clinics should hold onto.
The first is that ESHRE promotes blame-free near-miss reporting. The near miss is the signal. A lab that never records one is not a safe lab, it's a lab where nobody reports.
The second is what the HFEA data shows about scale. Across a reporting period the UK regulator logged 517 incidents and 89 near misses. Those are real numbers from real clinics operating under one of the strictest regimes in the world. So when a vendor or a competitor claims zero, treat it as a reporting failure rather than an achievement.
In 2018 two American clinics lost thousands of stored eggs and embryos in separate tank failures on the same weekend. What came out afterwards was not that alarms were absent. It was that alarms had been going off, had been repeatedly acknowledged and had stopped meaning anything. One case produced a verdict of nearly fifteen million dollars.
The lesson isn't buy more monitoring. It's that an alert nobody acts on is worse than no alert, because it manufactures a documented record of the clinic knowing. When you evaluate any system with alerting in it, ask what happens to an alarm that gets dismissed, whether repeat dismissals escalate to someone else and whether the pattern is visible to anyone above the person clicking it away.
Fertility drugs are cold chain, expensive and cycle critical. That combination is unusual. A stock-out in most specialties delays something. A stock-out mid-stimulation can abort a cycle the patient has already paid for and already prepared for emotionally, and it cannot be rescheduled by a week without starting again.
So the useful stock questions are narrower than general inventory. Not what's in the store, but what's committed to cycles already running, what expires before the cycles it's reserved for complete, and whether the person ordering can see both numbers at once. Batch and expiry tracking that links a specific vial to a specific patient's protocol is the difference between an inventory list and a system that prevents a cancellation.
Ask to see a cryo record for a sample stored eight years ago and check whether the consent, the disposition instruction and the tank position all come up together.
Ask what the system does at year nine of storage, and whether the alert reaches someone with authority to act.
Ask how donor uniqueness is enforced across the whole database, not per record.
Ask where embryo images are stored and whether they leave with an export.
Ask what an acknowledged alarm looks like in the audit trail and who can see a pattern of them.
And ask how the lab record links to whatever witnessing system you run, because they will always be two systems and the join between them is where accountability actually lives.
The lab bench: witnessing, culture, embryo tracking and connected devices.
Cryopreservation, sample tracking and chain of custody for frozen material.
Managing donor and recipient records across the ART bank.
Medicines from prescription to dispensing, with stock and expiry tracking.
